Cancer of the Pancreas Screening Study (CAPS 3) (CAPS 3)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00438906
Recruitment Status : Completed
First Posted : February 22, 2007
Last Update Posted : February 14, 2018
Lustgarten Foundation
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Marcia Irene Canto, MD MHS, Johns Hopkins University

February 20, 2007
February 22, 2007
February 14, 2018
December 2006
December 2009   (Final data collection date for primary outcome measure)
To determine the diagnostic yield of screening high risk patients [ Time Frame: 1 year ]
To determine the diagnostic yield of screening high risk patients (defined as relatives of patients with familial pancreatic cancer,patients with familial Peutz-Jeghers syndrome, and patients with germline BRCA2 and p16 mutations) for early pancreatic neoplasia using endoscopic ultrasonography, CT, and MRI/MRCP.
Not Provided
Complete list of historical versions of study NCT00438906 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Cancer of the Pancreas Screening Study (CAPS 3)
Screening for Early Pancreatic Neoplasia
The purpose of this study is to find the best and most sensitive screening modality (CT, MRI, EUS)for very small pre-cancerous pancreatic lesions and to treat these small lesions before they turn into cancer. Another purpose of this study is to search for common markers on DNA that would increase the chance of someone developing pancreatic cancer, and locate proteins in pancreatic juice that indicate tumor development.
Pancreatic cancer (PC) is the 4th leading cause of cancer death in the U.S. Because it is seldom diagnosed at an early curable stage, nearly all patients die from their disease. Early detection of PC and its precursors will save lives. In a multi-center, translational prospective controlled cohort study, we propose to screen high-risk individuals (members of familial pancreatic cancer kindreds and/or those with germline mutations of BRCA-2, p16, or STK-11), using EUS, CT, and MRI and test a panel of candidate biomarkers. Patients with suspected neoplasms will be offered surgery and the resected pancreata will be examined by an expert pathologist. Pathological results will be compared with radiologic findings and biomarker results. Our study hypothesis is that screening tests can detect early curable non-invasive pancreatic neoplasia in high risk individuals before it progresses to invasive cancer. The primary specific aim of this study is to determine the frequency of detectable pancreatic neoplasia in individuals with an inherited predisposition for pancreatic cancer. Our additional specific aims are: 1) To test the value of a newly-developed method (PANCPRO) of calculating the risk families have of developing PC so as to best target who might benefit from screening; 2a). To compare performance characteristics and reliability of the pancreatic imaging tests EUS, CT, and MRI/MRCP for the detection of early pancreatic neoplasia; 2b) To determine the prevalence of abdominal and pelvic tumors by CT and MRI in individuals carrying a germ-line BRCA2 gene mutation and patients with Peutz-Jeghers syndrome; 2c) To correlate radiologic abnormalities with histologic findings in resected pancreata; and 3). To validate a panel of candidate DNA and protein markers (CA19-9, macrophage inhibitory cytokine-1 (MIC-1), DNA hypermethylation, and KRAS gene mutations) in pancreatic juice and serum as indicators of prevalent neoplasms in high risk individuals, compared to concurrently enrolled controls.
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
approx 40 ml of blood, approx 10 ml pancreatic juice, pancreatic cells if fine needle aspirate is clinically recommended
Non-Probability Sample
People at risk for developing pancreatic cancer related to a strong family history of pancreatic cancer or carries a known genetic mutations associated with pancreatic cancer
  • Pancreatic Neoplasm
  • Peutz-Jeghers Syndrome
  • Procedure: Biopsy, Fine Needle Aspiration (FNA)
    If a pancreatic lesion of concern is identified, a small needle is inserted in the lesion in the pancreas and cells of the lesion are aspirated. Diagnosis of the lesion can typically occur with FNA.
  • Drug: Secretin (human synthetic) - ChiRhoClin
    Secretin is a synthetic human hormone that encourages the pancreas to create fluid. This will allow pancreatic juice to be collected via gentle suction in the duodenum where the pancreatic juice naturally flows.
    Other Name: Human Secretin
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
December 2009
December 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Persons with a verified family history of 2 or more first degree relatives with primary site pancreatic cancer(PC), age 40-80 years old or if 1 first degree relative also has at least 2 second degree relatives affected with PC.
  • Persons with a verified BRCA2 gene mutation or FAMM/p16 gene mutation, age 40-80 years old, and family history of pancreatic cancer.
  • Persons with Peutz-Jeghers Syndrome, 30-80 years old, and family history of pancreatic cancer.

Exclusion Criteria:

  • Persons with pancreatic cancer, or suspicious symptoms.
  • Persons who have had pancreas specific imaging protocol performed in the past three years.
  • Persons medically unable to have an endoscopy, CT or MRI procedure
Sexes Eligible for Study: All
40 Years to 80 Years   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
United States
3P50CA062924-13SB( U.S. NIH Grant/Contract )
Not Provided
Not Provided
Marcia Irene Canto, MD MHS, Johns Hopkins University
Johns Hopkins University
  • Lustgarten Foundation
  • National Cancer Institute (NCI)
Principal Investigator: Marcia I. Canto, M.D. Johns Hopkins University
Johns Hopkins University
February 2018